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ABSTRACT
Synthetic RNA formulations and viral vectors are the
two main approaches for delivering small thera-
peutic RNA to human cells. Here we report
findings supporting an alternative strategy in which
an endogenous human RNA polymerase (RNAP) is
harnessed to make RNA hairpin-containing small
RNA from synthetic single-stranded DNA oligo-
nucleotides. We report that circularizing a DNA
template strand encoding a pre-microRNA hairpin
mimic can trigger its circumtranscription by human
RNAP III in vitro and in human cells. Sequence and
secondary structure preferences that appear to
promote productive transcription are described.
The circular topology of the template is required
for productive transcription, at least in part, to sta-
bilize the template against exonucleases. In
contrast to bacteriophage and Escherichia coli
RNAPs, human RNAPs do not carry out rolling
circle transcription on circularized templates.
While transfected DNA circles distribute between
the nucleus and cytosol, their transcripts are found
mainly in the cytosol. Circularized oligonucleotides
are synthetic, free of the hazards of viral vectors and
maintain small RNA information in a stable form that
RNAP III can access in a cellular context with, in
some cases, near promoter-like precision and bio-
logically relevant efficiency.
INTRODUCTION
Small RNAs (sRNA) can have big effects on gene expres-
sion and other biochemical processes. Whether encoded
genomically or originating through design or laboratory
selection, sRNA from classes such as microRNA
(miRNA), small interfering RNA (siRNA), ribozymes,
short hairpin RNA and RNA aptamers have
demonstrated biological activity in vitro and in cells
(1–4). Biologically active RNA from these and related
sRNA classes hold promise for translation to clinical
applications if a general means to deliver them safely to
human tissues can be found (5).
Most sRNA intracellular delivery approaches fall
within two general categories. One is the direct chemical
synthesis of the sRNA (6) with modifications (7,8) and
nanoparticle (2,9) or liposomal (10) packaging to
enhance serum stability, tissue targeting and cellular
uptake. The other is based on gene therapy viral vectors
that carry the genetic information to make the sRNA, or a
pre-processed form of it (11–13). Viral vectors are attract-
ive because the otherwise labile and comparatively diffi-
cult to synthesize RNA sequence information is usually
held in the more stable form of DNA, and comes
packaged in its own delivery vehicle. However, viral
vectors carry many risks, including severe immune reac-
tions (14) and random integration of the DNA into
chromosomes, which can lead to cancer (15). In
addition, like other biologics, gene therapy vectors
cannot be characterized to the same extent as synthetic
compounds, and can therefore bring with them unnoticed
bio-contamination. They also suffer from poor nucleotide
(nt) economy, i.e. a high ratio of vector nt to mature RNA
nt, increasing the chances of off-target effects. Given the
cost and difficulties of using RNA directly, and the risks
associated with virus-based delivery vectors, alternative
approaches for producing sRNA in human cells are
needed.
Chemical DNA synthesis is simpler and more econom-
ical than RNA synthesis (16), with DNA chains over
100 nt now routinely made (17). We are investigating the
possibility that the cell’s own RNA polymerases (RNAPs)
can be harnessed to transcribe synthetic single-stranded
(ss) DNA into sRNA. To initiate transcription at
specific sites, RNAPs are widely understood to have a
general requirement for double-stranded (ds) DNA
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promoter sequences. It is, however, known that most
RNAPs can initiate ‘non-specifically’ on ss DNA
regions, a property that was often exploited to study
RNAPs before promoters were discovered (18). The
demonstrated ability of human RNAPs to initiate
promoterless transcription raises the possibility that
there exist certain sequences, secondary structures or
topological forms that might trigger, in the absence of a
canonical promoter, significant levels of precise transcrip-
tion on oligonucleotide templates.
Here we report that circularizing synthetic ss DNA
oligonucleotides can convert them into efficient templates
for RNAP III. We show that circular oligonucleotides, or
coligos (19), encoding RNA hairpin structures resembling
pre-miRNA, exhibit site-specific transcription initiation,
circumtranscription and predictable termination, leading
to the synthesis of discrete sRNA transcripts. In contrast
to previous reports on the promoterless transcription of
coligos by phage and bacterial RNAPs, in which the
RNAP was observed to transcribe many times around




Synthetic DNA Ultramer oligonucleotides with 50 phos-
phorylation were purchased from Integrated DNA
Technologies (Coralville, IA, USA). Enzymatic DNA cyc-
lization using the TS2126 RNA ligase, coligo purification,
RNA marker, denaturing polyacrylamide gel electrophor-
esis (DPAGE) were done as previously described (19). In
some cases, when the crude Ultramers were sufficiently
free of failure sequences to cyclize without prior gel puri-
fication, the DPAGE step was done after cyclization,
where it removed any unreacted linear form and the
(circular or linear) failure sequences, obviating the need
for a final exonuclease treatment. RNA secondary struc-
tures were predicted using the online version of the mfold
program (22). Escherichia coli RNAP was purchased from
USB. Yeast RNAP II was a gift from D. Bushnell and R.
Kornberg (23). General molecular biology methods were
done following standard procedures (24).
Cell culture and preparation of HEK293T whole
cell extracts
In a typical procedure, four 10-cm dishes of confluent
HEK293T cells grown in 1 Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% fetal
calf serum and Pen./Strep. were rinsed three times with
cold 1 phosphate buffered saline on ice. Then, 350–
700 ml lysis buffer [50 mM Tris–HCl pH 7.4, 150mM
NaCl, 1mM Ethylenediaminetetraacetic acid, 1% Triton
X-100 and Protease Inhibitor Cocktail (Roche, cat.
#04693159001)] was added per dish and incubated on ice
for 5min. Lysed cells were scraped to one side of the dish
and transferred with a 1-ml pipette tip to pre-chilled 1.5-
ml microfuge tubes. Cell lysis was continued for 5–10
more min on ice until the DNA was visibly precipitating.
The extract was centrifuged at 4C for at least 10min at
13.2 krpm to pellet genomic DNA and other insoluble
materials. The supernatant was transferred to a new
chilled tube, adjusted to a final glycerol concentration of
20% v/v, aliquoted and stored at 80C. The protein con-
centration was determined by Bradford assay (BioRad cat
# 500-0006) and ranged from 2 to 6 mg/ml depending on
the amount of lysis buffer used.
In vitro transcription
In vitro transcription (IVT) using whole cell extract (WCE),
uniform labeling with [a-32P]-UTP and the linear or circular
(coligo) templates was performed as follows. A typical 20ml
reaction mixture contained 25mg total WCE protein, 20
units RNase inhibitor (Promega), 1.25mM each adenosine
triphosphate (ATP), cytidine triphosphate (CTP), guanosine
triphosphate (GTP), 0.2mM uridine triphosphate (UTP),
[except Figure 1B, which contained 1.25mM each
nucleotide triphosphate (NTP)], 2mCi [a-32P]-UTP,
40mM Tris–HCl pH 7.9, 6mM MgCl2, 10mM
dithiothreitol (DTT), 2mM spermidine, 100mM NaCl,
100nM coligo template unless otherwise indicated. IVT
using E. coli RNAP (USB) was carried out in 40mM
Tris–HCl pH 8.0, 10mM MgCl2, 5mM DTT, 50mM
KCl, 50mg/ml bovine serum albumin, 1mM coligo
template, nucleotide triphosphate, 1.25mM NTP, 2mCi
[a-32P]-UTP, 1U/ml RNAse inhibitor. IVT with yeast
RNAP II was performed with 2.5mg purified enzyme in
40mM Tris–HCl pH 7.9, 6mM MgCl2, 10mM DTT,
2mM spermidine, 1.25mM NTP with 1mM coligo
template. Transcription reaction mixtures were incubated
for 90min at 37C, after which time the RNA was extracted
with 150ml TriReagent (Invitrogen) per 20ml reaction
volume, according to the manufacturer’s instructions, with
10mg glycogen added. After ethanol precipitation,
radiolabeled transcripts were separated over 9% DPAGE,
dried on Whatman paper and exposed to a Molecular
Dynamics Phosphorimager Screen. Images and quantitation
were performed using MD ImageQuant software. In
Figure 1B, the optimal coligo concentration for each
RNAP was used to show each enzyme at its most processive
and productive.
19aTAR RNA whole transcript cDNA sequencing
WCE IVT was scaled up 10-fold, and coligo-dependent
transcripts were separated from cellular sRNA using a
biotinylated probe chosen based on a preliminary 50
Rapid Amplification of cDNA Ends (RACE) experiment.
Linkers were added to the 30 and 50 ends, followed by
reverse transcription and nested polymerase chain
reaction (PCR). The PCR products were cloned into
pBluescriptSK. Miniprep DNA was isolated and
sequenced by Macrogen. See the Supplementary Data
for the detailed step-by-step procedure and selector,
linker and primer sequences.
122 RLM-RACE 50 end sequencing
WCE IVT was scaled up 10-fold and the single resolvable
83 nt transcript was located using film exposure, excised
and treated with 50 polyphosphatase. A 50 RACE adaptor
was added using Ambion’s RLM-RACE kit according to
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the manufacturer’s instructions. Reverse transcription was
primed using random hexamers, followed by PCR using 50
linker-specific forward primer and coligo-specific reverse
primers. The PCR product was cloned into pBluescript II
SK, and miniprep DNA was sequenced by Macrogen.
See the Supplementary Data for the detailed step-by-step
procedure.
122 RLM-RACE 30 end sequencing
WCE IVT was scaled up 10-fold and the isolated tran-
script was 30 extended using 5 units E. coli poly(A) poly-
merase, followed by reverse transcription using Ambion’s
30 RACE kit adaptor. The resulting cDNA was PCR
amplified using the Ambion 30 RACE inner primer and
a coligo-specific forward primer. The PCR product was
cloned into pBluescriptSK, and miniprep DNA was
sequenced by Macrogen. See the Supplementary Data
for the detailed step-by-step procedure.
Quantitative northern blotting of in vitro transcription
products
To make RNA quantitation standards and northern
probes, the linear precursors of coligos 122 and 19aTAR
were PCR amplified with primers containing BamHI and
EcoRI restriction sites, then directionally cloned into
pBluescript II SK, forming plasmids p122 and
p19aTAR, both of which have the ds form of the coligo
sequence under the control of the T3 and T7 RNAP pro-
moters in opposite directions. Uniformly labeled probes
complementary to the coligo transcripts were made from
linearized plasmids using T7 RNAP. Unlabeled RNA
standards complementary to the probe were made from
linearized plasmids using T3 RNAP in a 3-h 100-ml IVT.
Further details are provided in the Supplementary Data.
Template recovery from IVT reactions
In Figure 4A, each reaction was scaled up 4-fold to ensure
visualization of the templates by Stains-All dye. Here, 1 ml
of a one-tenth dilution of an RNase A/T1 mix (RNase
cocktail, Ambion) was added to each reaction and
incubated for 30 additional min at 37C. Nucleic acids
were isolated by phenol/chloroform/isoamyl alcohol ex-
traction and ethanol precipitation. After DPAGE, the
gel was soaked for 5min in ddH2O and stained with
Stains-All plus 1.25ml of formamide (diluted to 20ml
with ddH2O) for 30min, destained in ddH2O under incan-
descent light, dried on Whatman paper and scanned.
RNase H probing
At the end of a standard 90-min IVT, 1 unit of RNase H
(Promega) was added and the incubation was continued for
an additional hour. For the RNase H positive control lane,
the linear form of coligo 19aTAR was mixed with the
p19aTAR plasmid T3 RNAP run-off transcript, annealed
by heating 4min in 93C followed by slow-cooling. Isolated
total RNA from the same amount of WCE used in the IVT
reaction was added to normalize non-specific competition,
and RNAse H was added as above. RNA was isolated by
extraction with TriReagent, resolved by DPAGE and
exposed to a Phosphorimager screen.
Transfection of HEK293T cells and northern blotting
Twelve hours before transfection, HEK293T cells were
seeded in 12-well plates [1ml 1 DMEM with 10% fetal
bovine serum (FBS)], and then grown to 90% confluency.
Here, 46 ml of 1 DMEM was mixed with 4 ml of 10 mM
template stock in 10mM Tris-HCl/1mM EDTA (TE),
and 10 ml of PolyFect (Qiagen) was added and complexed
for 8min at room temperature. The non-transfected
control contained 46 ml 1 DMEM, 4 ml TE and 10 ml
PolyFect. From each well, 700 ml of the media was
removed, and the DNA complexes were added with
640 ml of fresh 1 DMEM supplemented with 10% FBS
(without Penn./Strep). After 24 h, or as indicated, the
RNA was harvested by lysing the cells of each well with
800 ml TriReagent and isolating the RNA according to the
manufacturer’s (Invitrogen) instructions. The pellet was
resuspended in 50 ml 1 DNase I buffer, 2 ml were
removed for OD260 measurement and the RNA was
digested with 4U of DNase I for 1 h at 37C. A volume
containing 12 mg of RNA was ethanol precipitated and
separated over 10% DPAGE (0.75 or 0.4mm gel thick-
ness), blotted onto BrightStar-Plus Positively Charged
Nylon Membrane (Ambion AM10102), baked for 20min
at 55C, UV-crosslinked, pre-hybridized in Church hy-
bridization buffer (0.25M Na2HPO4, 7% sodium
dodecyl sulphate, 1mM Ethylenediaminetetraacetic acid)
and hybridized in the same buffer at 55C overnight to a
uniformly labeled RNA probe transcribed from the ap-
propriate linearized plasmid (p19aTAR or p122). For
the LNA northern blots, 20 pmol of the miR-122 or -19a
LNA (Exiqon), complementary to the mature 122 and 19a
human miRNAs, were 50 end-labeled with [g-32P]-ATP/T4
Polynucleotide kinase, and used in place of the uniformly
labeled probe described above. Locked Nucleic Acid
(LNA) hybridization and washing were done also as
described above, except at 42C. Final northern blots
were washed twice for 30min each with Church wash
buffer (1% sodium dodecyl sulphate, 20mM Na2HPO4)
and exposed to a PhosphorImager screen (Molecular
Dynamics).
RNAP inhibitor use in vitro and in tissue culture
ML-60218 (Maybridge) was dissolved in
dimethylsulfoxide (DMSO) at a final concentration of
135mM and stored at 20C. Just before use, the stock
was diluted to 9mM and 67% DMSO with ddH2O. Only
at this dilution could ML-60218 be added to an IVT
reaction or transfection without precipitation of the
inhibitor.
a-Amanitin (Sigma-Aldrich) was dissolved in water at
1mg/ml and stored at 20C. For transfection experi-
ments, the inhibitor was added to the cells together with
the PolyFect-DNA complex and incubated for 9 h to
minimize cell death by prolonged exposure. Final concen-
trations were as follows: a-amanitin: low=0.12mg/ml,
medium=1.2 mg/ml, high=40 mg/ml; ML60218:
67.5 mM (2 IC50 RNAP III).
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RESULTS
Coligo transcription: RNA polymerase processivity and
evolutionary age
Before the discovery of miRNA and siRNA, coligos were
serendipitously found to undergo rolling circle transcrip-
tion (RCT; e.g. Figure 1A, nffi 12–260) (20) by isolated
RNAPs from bacteriophage and E. coli (20,21).
However, it has not been reported whether eukaryotic
RNAPs also transcribe coligos. The therapeutic potential
of sRNA makes this a timely and important question. To
investigate whether human RNAPs also carry out RCT,
we designed a coligo to code for a minimized primary
(pri)-miR-122 stem loop RNA [Figure 1A, and (19)]. In
the form of rolling circle transcripts (Figure 1A, n= large
number), coligo transcripts should fold into tandemly
arrayed multimers resembling naturally occurring
pri-miRNA from clustered miRNA genes. Indeed, we pre-
viously found that human Drosha could process RCT
transcripts made by purified E. coli RNAP (19).
Coligo 122 (Figure 1A) was made by circularizing a
synthetic 89 nt genomic sequence encompassing human
miR-122’s non-coding strand (19). Figure 1B shows an
IVT comparison of 122 with RNAPs from bacteria,
yeast (RNAP II) and human (HEK293T WCE).
Transcripts were visualized by [a-32P]-UTP incorporation.
RCT is recognized by the characteristic pattern of large
transcripts that enter the denaturing polyacrylamide gel
without migrating further (20) (Figure 1B, gel region
‘a’). As a relative measure of transcriptional processivity,
we calculated the ratio of the radioactivity incorporated in
the rolling circle transcripts (Figure 1B, gel region ‘a’ in
lanes 3, 6, 9) to the sum of all shorter transcripts (gel
region ‘b’). Lower a/b ratios indicate lower transcriptional
processivity. A comparison of lanes 3, 6 and 9 reveals a
clear trend in which a/b declined from E. coli to human
RNAPs. Thus, the ability to initiate promoterless tran-
scription on coligo templates appears to have been
retained during RNAP evolution, whereas the processivity
needed for RCT appears to have been lost.
Precise coligo transcription by a human RNA Polymerase
Although no RCT was observed, transcription of coligo
122 by the human WCE was remarkable for having
produced a single, well-defined and relatively abundant
in vitro transcript, possibly indicating transcription initi-
ation and termination at specific sites. The size similarity
between coligo 122 (89 nt) and its transcript (83 nt)
indicated that the putative initiation and termination
sites were close. About 4% of transcription events read
through one time and terminated on the second pass,
producing a tandem dimer transcript at 160 nt.
Interestingly, although no RCT treadmill action on the
coligo was needed to produce the single round
(monomer) transcript, the circular topology of the coligo
sequence was required (Figure 1B, lane 8 versus 9). Thus,
the circular topology of coligo 122 appeared to promote
transcription by 1 human RNAPs, and termination, or
termination followed by rapid processing occurred
non-randomly just upstream of the site of initiation.
In an initial test for generality, we made three additional
coligos (Figure 1C) similar in size and design to 122,
including one based on another human pre-miRNA,
miR-19a (19). Figure 1D shows the RNA products
formed during IVT in HEK293T WCE using these tem-
plates in both linear (L) and circular (C) form. Coligo 19a
was a poor substrate, but 19aTAR, which contains the
same 19a miRNA stem but different terminal loops,
templated the synthesis of three resolvable and relatively
abundant transcripts. Coligo 122TAR, which contains
the 122 stem but different loops, produced six resolvable
transcripts. As observed for 122, the transcripts from
19aTAR and 122TAR were slightly shorter than their
template, low levels of dimer transcripts resulted from
read through and the linear forms did not template pro-
ductive transcription. Taken together, these results
showed that single round transcription was not peculiar
to coligo 122, and that sequence variations outside of the
miRNA-encoding stem at least in part determine tran-
scription efficiency and the sites of initiation and
termination.
We probed the 50 end of the 19aTAR transcripts using
50 end modifying enzymes (Supplementary Figure S1).
Neither a 50 phosphate-dependent 50!30 exonuclease (‘ter-
minator 50-phosphate-dependent exonuclease’, Epicentre),
nor sequential treatment with tobacco acid pyropho-
sphatase, which reduces 50 cap structures to a 50 phos-
phate, followed by the terminator exonuclease, altered
the pattern of coligo-dependent transcripts. This result
indicated that the transcripts are not 50 capped or
mono-phosphorylated. Two different enzymatic treatment
sequences provided evidence that the transcripts are, as
expected, 50 triphosphorylated, but also have terminator
exonuclease-impeding secondary structure. Polypho-
sphatase, which reduces triphosphate tails to single phos-
phates, followed by the terminator 50 exonuclease,
shortened but did not fully degrade the transcripts. The
same result was obtained when complete dephos-
phorylation was followed by 50 mono-phosphorylation,
and then terminator exonuclease treatment. While the in-
complete digestion that was observed could signal the
presence of an unexpected 50 modification in some tran-
scripts, or no modification at all, the simplest explanation
is that the 19aTAR transcripts have, as expected, a 50 tri-
phosphate and secondary structure near the 50 end that
stops the 50!30 terminator exonuclease from fully
degrading the transcripts.
Adding linkers to, and sequencing the cDNA of, the
110 nt 19aTAR transcripts revealed a single transcription
start site (13/13 clones) in the larger ss loop (Tss,
Figure 1E). About half (6/13) of the cloned transcripts
appeared to terminate precisely at a dC just upstream of
Tss. This putative termination site immediately preceded
an A5 run, a sequence that in a ds DNA context is a strong
RNAP III termination signal (25). All other transcripts
appeared to terminate either just before or just after this
position. The 30 ends may result from termination with or
without subsequent 30!50 processing. Abundant cellular
RNA in the same size range made cDNA sequencing dif-
ficult. We therefore used 50 and 30 RACE procedures to
obtain a composite sequence for the 83 nt 122 transcript
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Figure 1. Transcription of coligos by RNAPs. (A) Schematic illustration showing the sequence and predicted secondary structure of a coligo and its
RNA. Coligo 122 was taken from the template strand of the human gene encoding miR-122. The subscript n denotes number of tandem repeats.
RCT produces n » 1; n 1 indicates single round transcription leading to monomer transcripts. Small arrow: circularization site, linear forms are
discontinuous here with 50 phosphate. Shaded region, mature miR-122 or its cDNA. nt, size in nucleotides. (B) IVT of coligo 122 by RNAPs of
varying evolutionary age and complexity. E. coli RNAP, yeast RNAP II and human RNAPs from HEK293T WCE were used for IVT. RNA was
visualized on a denaturing polyacrylamide gel (DPAGE) by uniform [a-32P]-UTP incorporation. L, linear; C, coligo. Lanes 1, 4, 7: no template. M,
RNA marker. Relative processivity (Proc.) defined by the a/b ratio, and relative exposure (Exp., i.e. Phosphorimager grayscale setting difference) are
indicated. (C) Sequences and predicted secondary structures of coligos 122TAR, 19a and 19aTAR. (D) IVT using HEK293T WCE followed by
DPAGE analysis of uniformly labeled transcripts. Dimer transcripts read through the termination site one time to produce tandem dimer transcripts.
(E) Sequence analysis of transcripts made by human WCE from coligo template 19aTAR. The 19aTAR IVT products were isolated and their cDNA
sequenced. Tss, transcription start site. (F) Sequence analysis of transcripts made by human WCE from coligo template 122. The 122 IVT product
was isolated and sequenced using 50 and 30 RLM-RACE protocols.
2556 Nucleic Acids Research, 2013, Vol. 41, No. 4
(Figure 1F). This transcript also began exclusively in the
larger of the two terminal loops of the coligo and, similar to
the 19aTAR case, mainly at one pyrimidine nt near
the helix stem (Figure 1F, Tss, 23/27 clones).
Transcription termination (or 30 end formation) of coligo
122 occurred just after a known RNAP III termination
signal (AAACA) (26). Thus, although ss and promoterless,
coligos 19aTAR and 122 both underwent precise transcrip-
tion initiation to produce stable hairpin RNAs with low 30
end heterogeneity.
Transcription of hairpin-encoding coligos is a general
property of human cellular extract
We made additional coligos to probe the structural deter-
minants of monomer circumtranscription. (See
Supplementary Figure S2 for these coligo sequences and
predicted secondary structures.) First, in an effort to
produce a transcript more closely resembling a typical
pre-miRNA, we removed an 18 nt section of the coligo
122 stem, shown boxed in Figure 1F. Removal of this
section did not appear to change the sites of initiation
and termination, as the resulting coligo, 122 s, was
transcribed into the 65 nt transcript expected if the 122
start and stop sites were used, although the amount of
the monomer transcript was significantly lower after
taking into consideration the labeling difference (Figure
2A, Gel 1). This result showed the stem could be altered
while maintaining loop-directed start and stop sites, but
also that the stem length and/or sequence somehow con-
tributes to transcription efficiency. Coligo 19aTAR
contains a terminal stem–loop encoding the HIV trans-
activation response element TAR (Figure 1C). The TAR
loop increases transcriptional processivity in HIV RNAP
II transcripts (27), and was added to 19a in an effort to
stimulate transcriptional elongation before we learned
that RNAP III was responsible for coligo transcription
(see below). To gauge the effect of the TAR sequence on
coligo transcription efficiency, we changed its sequence
entirely, while keeping a similar secondary structure. The
resulting coligo, 19am3 (Supplementary Figure S2), was
transcribed similarly to 19aTAR, showing that the TAR
loop encoding sequence was not important for transcrip-
tion, but that its secondary structure, including its small
terminal loop, might contribute to transcription (Figure
2A, Gel 2). This conclusion was further supported by
coligo 19aRL (Supplementary Figure S2), where the
TAR loop was changed to a large unstructured
sequence. This coligo, which has two large ss terminal
loops capping the miRNA-encoding stem, produced no
observable transcripts (see below). These results suggest
that, for transcription to occur in human cell extract, a
coligo should have an imperfect ds stem and one large and
one small terminal ss loop, the larger of which, where
transcription is likely to initiate, should not be
pyrimidine-rich (e.g. coligo 19a).
We tested four additional coligos, three based on
randomly selected human miRNAs (hsa miR-221, -15
and -21) and one on an siRNA complementary to the
luciferase 30 UTR, luc-1 (28). In a manner similar to
coligos 122, 122s, 19am3 and 19aTAR, we designed each
to have a larger purine-rich terminal loop at one end with
a pyrimidine near the stem–loop junction, and a smaller
terminal loop at the other end. The genomic template
strand sequences used in the design of coligos 221 and
15a, like those of 122 and 19aTAR, contained RNAP III
termination sequences near the stem–larger loop junction
(bold in Supplementary Figure S2). In coligo luc-1, two
artificial A5 sequences were added to the larger loop. No
RNAP III termination sequences were found or put in
coligo 21. As shown in Figure 2A (Gels 3 and 4), all
four coligos were transcribed in HEK293T WCE to
monomer transcripts having a size approximately that pre-
dicted by initiation and termination similar to those found
in 19aTAR and 122 (see Supplementary Figure S2 for
expected start and stop sites). However, there were some
differences. Coligo 21 gave rise to significant amounts of
larger tandem transcripts, possibly explained by its
complete lack of any sequence resembling a RNAP III
termination sequence. Coligo luc-1’s monomer transcript
was significantly less abundant than the others, which may
be the result of the A5 sequence present between the
putative starting pyrimidine and the stem
(Supplementary Figure S2). Overall, the transcriptional
behavior of these additional coligos was similar to that
of 19aTAR and 122, indicating that coligo circumtran-
scription is a general activity of HEK293T WCE.
Although there are differences in efficiency, precision
and read through, and more examples will need to be
studied to attain consistent control, our most precise
example, coligo 122, shows that the transcriptional preci-
sion from these chemically synthesized templates can
approach that of canonical ds RNAP promoters.
The results from the tested coligos allowed us to formu-
late a preliminary description of the features that lead to
successful circumtranscription resulting in an RNA
hairpin (Figure 2B). They include one large relatively
purine-rich loop and one smaller loop flanking an imper-
fect ds stem; a pyrimidine close to the 30 end of the stem/
larger loop junction where in the two sequenced cases
transcription initiated; an RNAP III termination
sequence either in the larger loop or near the 50 end of
the stem–large loop junction. On this last point, we specu-
late that, based on coligo 21, which has no such sequence,
the junction structure itself may contribute to termination
even when no RNAP III termination signal is present.
Indeed, the RNAP III termination sequences were
merely associated with nearby transcription termination,
and we cannot be certain they function as they do in a ds
DNA context. (Exonuclease trimming in the 30!50 direc-
tion may also contribute to 30 end formation.) With these
features in mind, we made and tested a coligo that had
none of these characteristics, coligo RANDC1
(Supplementary Figure S2). This coligo has the same
G+C and A+T content as 19aTAR. It was produced by
a random sequence generator and chosen because it had as
little predicted structure as could be generated. This coligo
produced no detectable transcripts (Figure 2A), support-
ing the hypothesis that there are sequence and secondary
structure rules that must be followed for successful coligo
transcription to occur.
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Nanomolar coligo levels lead to biologically relevant
transcript levels
We used quantitative northern blotting to estimate the
amount of single round transcripts formed as a function
of coligo concentration (Figure 3A and B). Single round
transcripts from 19aTAR were detectable using as little
as 10 nM coligo, and increased to an RNA concentration
of 0.6 nM transcribed from 100 nM coligo. Raising the
coligo concentration eventually reduced the amount of
transcript. In the case of coligo 122, single round tran-
scripts were detectable at 100 pM coligo, and a plateau
of 6 nM transcript was reached at 50 nM coligo. A
time course showed that RNA levels continued to
increase up to 2.5 h, the longest time point monitored
(Figure 3C). No trace of longer transcripts were seen
at early time points, indicating either that 30 exonuclease
trimming does not contribute to transcript 122’s 30 end,
or that such trimming is too fast to observe by this
method.
To put coligo transcript levels into perspective, we
compared the single round transcript level from 19aTAR
with the mature miR-19a in HEK293T extract. Based on
RNA-Seq experiments in the closely related HEK293 cell
line, miR-19a is moderately to highly expressed in HEK
cells (29). Endogenous miR-19a in the HEK293T WCE
(Figure 3D) was visualized using a standard LNA
northern probe visualizing both transcripts with equal sen-
sitivity. The coligo 19aTAR transcript at 90min was
65-fold higher than the endogenous miR-19a in WCE.
Thus, a coligo template can quickly be transcribed by
HEK293T WCE to a level beyond that of a moderately
expressed endogenous miRNA.
Coligo and transcript are stable to cellular nucleases, but
do not remain hybridized
Figures 1 and 2 showed that the coligo’s circular topology
is required for productive transcription, although—and in
contrast to RCT—no treadmill action should be required
to produce single round transcripts. To test whether
transcribability correlated with stability against cellular
nucleases, we attempted to recover linear and coligo tem-
plates at the end of a WCE IVT reaction. Figure 4A shows
that while coligos were stable in HEK293T WCE, their
linear forms were degraded. Coligo 19aRL
(Supplementary Figure S2), where the structured TAR
loop of 19aTAR was replaced by an unstructured loop,
was stable but not transcribed (Figure 4B). Thus, a
circular topology appears necessary but not sufficient for
an oligonucleotide to undergo specific transcription and,
as stated above, certain sequence and secondary structure
rules must be met for transcription to occur.
Our data show that both coligo and transcript are stable
in WCE. Promoterless transcription from 30 tailed tem-
plates can lead to transcription events ending in a stable
RNA:DNA hybrid (30). While the fact that stable coligo
transcripts are observed argues against the presence of
extensive RNA:DNA hybrids, whose RNA would be
subject to cellular RNase H degradation (31), we further
tested for RNA:DNA hybrid formation by adding supple-
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Figure 2. Coligo secondary structure contributes to transcription by human WCE. (A) IVT of indicated coligos, as in Figure 1. Coligo sequences and
predicted secondary structures are shown in Supplementary Figure S2. Brackets indicate predicted monomer transcript size (10 nt window) based on
sequencing data shown in Figure 1E and F. Gel 1: The boxed sequence shown in Figure 1F was removed from coligo 122 to produce 122s, whose
transcript size changed accordingly. Ratio is for monomer transcripts at 83 and 65 nt, adjusted for label content. Gel 2: The TAR loop encoding
sequence in coligo 19aTAR was changed while keeping a similar secondary structure to produce coligo 19am3, which was similarly transcribed. Gel 3:
Coligos 221 and 15a are based on the human miRNAs of the same number. Luc-1 encodes a pre-miRNA complementary to a luciferase 30 UTR
sequence. Each coligo was transcribed by WCE to predicted monomer-size transcripts (brackets). Gel 4: RANDC1 encodes a largely unstructured
transcript. Coligo 21 is based on human miR-21 and contains no RNAP III termination sites. It produces less monomer transcript and more tandem
multimer transcripts. (B) Schematic summary of sequence and secondary coligo features that appear to promote discrete transcription events
in WCE.
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Exhaustive RNase H activity (lanes 1 and 2) had no effect
on the 19aTAR transcripts (having 38 predicted bp, Figure
1E), while 20% of the 122 transcripts (having 32 pre-
dicted bp, Figure 1F) were susceptible to added RNase H.
We conclude that the strong intramolecular secondary
structure of coligo and transcript favor release of the tran-
script, although a fraction can remain hybridized when
there are relatively few bp in the stem. This result also
rules out the possibility that the RNAP terminates after
single round transcription because it encounters—and
cannot unwind—a persisting RNA:DNA hybrid at the
transcription start site. Instead, termination must be
caused by other factors.
Coligo transcription in human cells
We next asked whether coligos can enter and undergo
transcription in human cells. Coligo 19aTAR and its
linear counterpart were transfected into HEK293T cells
at 40 nM. Including 32P-labeled tracers of the same
DNA revealed that 50% of the linear and coligo tem-
plates entered the cells and remained stable during a 24-h
experiment (Figure 5A). Three coligos that were
transcribed in vitro were transfected into HEK293T cells
and assayed by northern blotting of total cellular RNA
after 24 h. In each case, transcripts the sizes of those seen
in vitro were detected (Figure 5B). After 24 h transfection,
the 19aTAR transcript was found at 26-fold greater
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Figure 3. Coligo concentration dependence and RNA transcript quantitation for HEK293T WCE IVT. (A) Quantitative northern blotting of coligo
19aTAR IVT transcripts. The indicated range of coligo concentrations was used in unlabeled HEK293T WCE IVT reactions and the transcript levels
were compared with known amounts of RNA containing the same northern probe recognition sequence. Numbers below blot indicate transcript
molarity estimated after 90min IVT. Endogenous 7SK RNA was probed separately as a loading control. Asterisk (*) indicates the single round
transcript whose concentration estimates are listed below gels. (B) Quantitative northern blotting of coligo 122 IVT transcripts, as in panel A.
(C) Time course for 100 nM coligo 122 IVT, visualized by [a-32P]-UTP incorporation. Rel. RNA: relative amount of RNA. (D) Quantitative LNA
northern blot comparison of endogenous HEK293T miR-19a with the 90min IVT transcripts made from coligo 19aTAR (100 nM), in the same
extract. The ratio of the 19aTAR in vitro single-round transcript (110 nt) to endogenous miR-19a (23 nt) is 65. Full LNA northern signal
cross-reacting with the DNA input templates, in absence of DNase treatment, can be seen in lanes 5 and 6. In lanes 3 and 4, the DNA templates
were added to HEK293T extract and immediately processed without IVT incubation period to show that DNase I treatment of templates ensures
they have no detectable signal in the northern blots shown in panels (A–C).
Nucleic Acids Research, 2013, Vol. 41, No. 4 2559



































































1 2 3 4 5 6 7 8
A B C
Figure 4. Coligo topology is necessary but not sufficient to template the synthesis of stable released sRNA transcripts in human WCE.
(A) Circularization stabilizes oligonucleotides in human WCE. Circular (C) or linear (L) templates (Input) were recovered (Post) from HEK293T
WCE IVT, digested with RNase cocktail to reduce cellular RNA, and stained after DPAGE. Linear forms were degraded during IVT; coligos were
stable. Coligo 19aRL sequence is shown in Supplementary Figure S2. (B) DPAGE separation of HEK293T WCE IVT of the three coligos and linear
precursors from the reactions shown in panel A. (C) Transcripts are released from the coligo template during IVT. RNase H (RH) was added to (+)
or withheld from () the indicated coligo IVT reactions at the end of a typical 90-min incubation period. Following additional incubation, the RNA
products were separated by DPAGE. Lanes 1 and 2, validation of exhaustive RNase H activity on a 32P-RNA:DNA hybrid. Reaction in lane 2 was
supplemented with total HEK293T cellular RNA to normalize non-specific competing RNAs among all RNase H reactions. The result shows that
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Figure 5. Coligo transcription in human cells. (A) Fate of transfected coligo and linear templates. 32P-labeled DNA tracers were spiked into
unlabeled templates and transfected at 40 nM into HEK293T cells using PolyFect transfection reagent. Templates recovered from harvested cells
(‘in’) and media supernatant (‘out’) were adjusted to equal percentages of total fractions, and separated by DPAGE. C, coligo; L, linear; M, RNA
marker. About half of the DNA entered cells during transfection. (B) Coligos are transcribed in human cells. Templates (C or L) were transfected
into HEK293T cells for 24 h after which time total RNA was assayed by northern blotting using a 50 labeled template-specific LNA. The ratio of the
19aTAR single round transcript (110 nt) to endogenous miR-19a (23 nt) is 26. Endogenous 7SK RNA was probed separately as a loading control.
(C) RPA on total RNA isolated from cells transfected with coligo or linear 19aTAR. p, probe input; p+, probe alone digested with RNase cocktail.
(D) Coligo transcripts accumulate during transfection period. Total RNA of cells transfected with coligo 19aTAR harvested after the indicated
transfection times and probed by northern blotting using a uniformly labeled in vitro RNA transcript complementary to one complete coligo
transcript sequence. 7SK, loading control.
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abundance than the mature miR-19a (Figure 5B, right
panel). Although apparently stabilized by the transfection
reagent (Figure 5A), the linear forms produced no detect-
able transcripts, underscoring the strict requirement of the
circular topology for productive transcription in cells,
apart from the stability conferred by circularization. The
importance of the circular topology in vivowas further sup-
ported by an RNase protection assay (RPA) performed on
total RNA isolated from transfected cells (Figure 5C).
Here, the temperature of the assay was lower than the
northern hybridization temperature, enabling the detection
of aborted transcripts. Both the linear and coligo forms of
19aTAR templated a small fragment at30 nt, but only the
coligo underwent circumtranscription. A time course fur-
thermore showed that the 19aTAR transcript continued to
increase over a 24-h transfection period (Figure 5D).
Overall, Figure 5 shows that transcription in cells parallels
transcription in vitro: a circular template is required, single
round transcripts slightly smaller than the coligo are made
and the coligos template the accumulation of stable tran-
scripts over time.
Coligos are transcribed in vitro and intracellularly
by RNAP III
To learn which of the human RNAPs is responsible for
coligo transcription, we took advantage of their different
susceptibilities to the transcription inhibitor a-amanitin
(32). IVT of coligo 19aTAR was carried out using
HEK293T WCE in the presence of increasing concentra-
tions of a-amanitin. At 0.12mg/ml, a concentration that
only inhibits RNAP II (32), coligo transcription was un-
affected, ruling out RNAP II (Figure 6A). At 120 mg/ml,
which completely inhibits RNAP III but not RNAP I, no
coligo transcripts were produced, implicating RNAP III.
Similar results were obtained when coligo 19aTAR was
transfected into HEK293T cells in the presence of
increasing amounts of a-amanitin, followed by northern
blotting of total cellular RNA with a 19aTAR-specific
probe (Figure 6B). To further test the identity of the
RNAP, we treated HEK293T cells with ML-60218, an
RNAP III-specific inhibitor (33). Northern blotting
showed that no single round transcripts were produced
in ML-60218-treated cells transfected with coligo
19aTAR (Figure 6C). These results demonstrated that
RNAP III is responsible for producing all transcripts
from coligo templates in vitro and in human cells.
Subcellular fractionation of transfected coligos and
coligo-derived transcripts
Promoter-independent RNAP III activity was recently
found in the cytosol of HEK293 cells, where its transcrip-
tion of poly(dA-dT) revealed an unexpected role for the
polymerase in the innate immune system (34,35). RNAP
III was found to transcribe poly(dA-dT), a viral DNA
surrogate, into ds RNA, which in turn activated an inter-
feron response through the RIG-I helicase. Because
coligos also undergo promoterless transcription, and
because A/T-rich DNA is prone to forming transient
loops that might resemble A-rich coligo loops, we
wondered if coligos might be transcribed in the cytosol
by engaging this natural process. We therefore tracked
the sub-cellular location of the coligo and its transcripts
during subcellular fractionation. A radiolabeled coligo
was transfected into HEK293T cells and found to be
evenly distributed between nuclear and cytosolic fractions
(Figure 6D). In contrast, northern blotting of the
fractionated extracts from coligo 19aTAR-transfected
cells showed that 90% of the coligo transcripts were in
the cytosolic fraction (Figure 6E). To verify that the
cytosol fraction contained RNAP III capable of coligo
transcription, we fractionated untransfected HEK293T
WCE, verified that a significant amount of RNAP III
was present in both nuclear and cytosolic fractions
(RPC2 western blotting, Figure 6F) and carried out IVT
with and without RNAP III inhibitors. The results showed
clearly that RNAP III in both cytosolic and nuclear frac-
tions carried out strong coligo transcription similar to the
pattern generated by WCE (Figure 6F). While we cannot
rule out the possibility that the cytosolic transcripts in
Figure 6E were made in the nucleus and exported to the
cytosol, or that half of the nuclear RNAP III leaked into
the cytosol during the fractionation procedure, until a
promoter-independent role for RNAP III in the nucleus
is found, the simplest explanation is that the coligo was
transcribed mainly by RNAP III in the cytosol. These data
support the hypothesis that coligos are primarily
transcribed in the cytosol through fortuitous engagement
of RNAP III’s pathogen-recognition role in innate
immunity.
DISCUSSION
Here we report the unexpected finding that circularizing
synthetic oligodeoxynucleotides can result in their use as
transcription templates by RNAP III in vitro and in
cultured human cells. Promoter-independent transcription
by mammalian RNAPs is known to initiate at internal ss
regions such as nicks and gaps in otherwise ds DNA (18),
and site-specific promoterless transcription has been regu-
larly used on 30 ss tailed ds DNA (30,36). Our templates,
however, are ss and circular, and thus without free 30 ends,
nicks or gaps, and reveal a previously unrecognized means
to initiate site-specific de novo promoterless transcription
by a mammalian RNAP in vitro and in human cells.
Because biologically active sRNA falls squarely within
the size range of currently accessible synthetic DNA, our
findings have the potential to form the basis of a new class
of sRNA delivery vectors made by the chemical synthesis
of promoterless DNA templates able to be read by human
RNAP III. In addition, we find that the circular topology
required for single round transcription of the coligos
protects them from nuclease degradation in WCE.
Circularization of oligonucleotides has previously been
shown to stabilize ss DNA against degradation in
human serum (37). Thus, one of the defining structural
determinants promoting coligo transcription stabilizes
the coligo in a biological context.
Although we found that circularization conferred sta-
bility against intracellular nucleases, it was not sufficient
to trigger productive transcription; a hairpin-encoding
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secondary structure in the coligo was also required,
possibly to mimic a natural transcription intermediate
(see below), and possibly to favor intramolecular
base-pairing over persistent RNA:DNA hybrid formation,
which would lead to RNase H susceptibility. Hairpins
constitute the basic unit of sRNA secondary structure.
As such, coligos may prove generally suitable for the tran-
sient ectopic expression of a wide variety of functional
sRNA in human cells. Random sequences with insignifi-
cant stem lengths, like RANDC1, or coligos with a highly
pyrimidine-rich larger loop, like 19a, or two large terminal
loops, like 19aRL, appear not to fulfill the requirements
for transcription or the transcription of stable transcripts.
Our choice of pre-miRNA–like stem loop RNA as
proof of principle transcription targets called for DNA
coligos consisting of an imperfect stem capped by
terminal loops, including one small loop to encode the
pre-miRNA terminal loop. Productive synthesis of single
round transcripts resulted when the loop at the other end
of the imperfect stem, which in most cases was derived
from pri-miRNA flanking sequence, was larger
(11–22 nt) and adenine rich (33–68%), but not larger
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Figure 6. RNAP III is responsible for coligo transcription, which appears to take place mainly in the cytosol of transfected cells. (A) a-Amanitin
inhibits coligo transcription at concentrations consistent with RNAP III transcription. HEK293T WCE IVT was carried out with increasing con-
centrations of a-amanitin. C, coligo 19aTAR, 100 nM. Lanes 3–5: 0.12, 1.2, 120mg/ml a-amanitin. Rel. SRT: relative amount of single round
transcript (aka monomer transcript). (B) Northern blot of total RNA from HEK293T cells transfected with 40 nM coligo 19aTAR with concurrent
a-amanitin treatment (Lanes 3–5: 0.12, 1.2, 40 mg/ml). 7SK RNA was probed as a loading control. (C) Northern blot of total RNA from HEK293T
cells transfected with 40 nM coligo 19aTAR with concurrent RNAP III-specific inhibitor ML-60218 treatment at 68 mM. DMSO, inhibitor solvent.
U2 snRNA was probed as loading control. (D) DPAGE of 32P tracer-labeled coligo 19aTAR recovered from HEK293T transfection after separation
of nuclear and cytosolic fractions. Equal percentages of the nuclear and cytosolic fractions were loaded. Inset: western blot assessment of fraction-
ation, b-tub., b-tubulin (cytosolic protein). H4, histone H4 (nuclear protein). M, markers and input templates. (E) Northern blot of RNA isolated
from HEK293T nuclear and cytosolic fractions 24 h after transfection with 40 nM coligo 19aTAR. Equal percentages of the nuclear and cytosolic
fractions were loaded. Inset: western blot assessment of fractionation, as in panel D. (F) HEK293T nuclear and cytosolic extract IVT in the presence
of increasing a-amanitin (a, lanes 3–5 and 10–12: 0.12, 1.2 and 120mg/ml), DMSO (D) or ML-60218/DMSO solution (ML). Inset: western blot
assessment of fractionation, b-tub., b-tubulin (cytosolic protein). CstF-77, (nuclear protein); RPC2, RNAP III subunit.
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and pyrimidine rich (e.g. 19a) or if there were two large
loops (e.g. 19aRL). Transcript sequencing of 122 and
19aTAR showed nearly homogeneous transcription initi-
ation at a specific pyrimidine, flanked by purines, in the
larger loop 2–4 nt from the 30 end of the stem, a structural
feature that may prove to be a general coligo initiation
motif. A loop directly adjacent to a stem may recruit
RNAP III by locally mimicking an intermediate structure
on the path to promoter-dependent transcription. The
greater degree of conformational freedom in the linear
templates may fail to stabilize such a structure long
enough for transcription to begin, at least in the time
before the linear templates are degraded by cellular exo-
nucleases. Furthermore, in a cellular context and in
cellular extracts, other ss DNA-binding proteins may
compete with RNAP III for the coligo loops, reducing
RNAP III initiations—a potential limitation that might
be overcome by loop sequence optimization. Such ss
DNA-binding proteins might also contribute to transcrip-
tional pausing and termination in the absence of a RNAP
III termination signal (e.g. 21) by obstructing processive
transcription. Given an imperfect ds stem capped by one
large and one small loop, the larger loop’s size, sequence
and secondary structure appear to control initiation and
termination (or 30 end formation), and efficient larger
loops, like natural promoters, may be transferable to
other hairpin stems.
Our identification of RNAP III as the enzyme respon-
sible for coligo transcription has the potential to lead to
general applicability because termination appears to be
controlled, in an as yet undefined manner, by this
enzyme’s simple termination signals (possibly followed
by exonuclease processing). The need for these sequences
might be considered a limitation because they should not
occur in the middle of a desired sRNA sequence.
However, we note that the relatively strong RNAP III
termination sequence A4 occurs in the stem of 19aTAR,
yet no termination was found there, whereas the weaker -
AAACA- signal (26) at the stem–loop junction appeared
to direct strong termination in the larger loop of coligo
122. It is possible that termination signal strength can be
modulated by the coligo’s secondary structure context. We
also acknowledge that RNAP III termination signals as
they occur in ss coligos may not function the same way
they do in natural ds templates, as the coding strand is not
present in the coligo. Nevertheless, the modest 30 end het-
erogeneity that resulted from termination on the 122 and
19aTAR templates in vitro is not different from that seen
in the deep sequencing of naturally occurring miRNA (38)
and pre-miRNA (39,40), though the 30 ends of endogen-
ous pre-miRNA result from Dicer processing. Because
some, if not most, coligo transcription appears to occur
in the cytosol, where Dicer functions, it remains possible
that the 50 and 30 ends of coligo transcripts may be suitably
prepared for Dicer by initiation and termination on a
coligo template, as opposed to the natural case of
pri-miRNA Drosha processing in the nucleus.
Promoterless RNAP III activity was previously found in
cytosolic extracts (18,32). The recent discovery that RNAP
III functions in the innate immune system as a sensor of
pathogenic ds DNA invading the cytosol may explain its
location there (34,35). Transfected poly(dA-dT) was found
during the innate immune system studies to be transcribed
in the cytosol by RNAP III (35). Though intracellular
leakage is always a possibility in fractionation-based ex-
periments such as ours, coligos appear to be transcribed
by cytosolic and nuclear RNAP III. Nevertheless, the tran-
scripts from transfected coligos localized mainly to the
cytosol, an asymmetry that cannot be explained by
leakage. Taken together, our data support a model in
which transfected coligos distribute throughout cells but
are transcribedmainly in the cytosol, by RNAP III presum-
ably diverted from its innate immunity role. Promoterless
nuclear transcription followed by export is less likely, given
that pre-miRNAs with ss extensions suffer from poor
export (41,42). Transcription of poly(dA-dT) makes
self-complementary poly(rU-rA), which in turn activates
interferon production via RIG-I, an RNA-binding
protein preferring fully base-paired, blunt-ended ds RNA
with a 50 triphosphate (43). We found evidence that coligo
transcripts are not capped or 50 mono-phosphorylated, and
that at least some bear a 50 triphosphate. Learning the rules
governing the precise coligo transcription initiation and
termination observed here may allow RNAP III’s innate
immunity activity to be engaged without triggering an
immune response, as two of the three RIG-I recognition
features (blunt ends, and fully base-paired stems) can be
avoided when designing coligo templates.
More work will be needed to predictably control RNAP
III initiation and termination on coligo templates
encoding any desired RNA hairpin sequence, but coligos
122 and 19aTAR demonstrate that precise control is at-
tainable. Our findings therefore have the potential to
recast the sRNA delivery problem into a more tractable
one in which the synthetic informational molecule that
requires intracellular delivery is more stable and simpler
to synthesize than synthetic RNA, and likely free of the
dangers posed by viral vectors. Although lacking canon-
ical transcriptional promoters, coligos having certain
features can promote oligonucleotide transcription by
RNAP III, and provide an alternative approach to syn-
thetic RNA and viral vectors as a means to generate bio-
logically active sRNA in human cells.
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